For the quarter ending 2025-09-30, SIGY made $386,529 in revenue. -$578,503 in net income. Net profit margin of -149.67%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Income taxes | 0 | 0 | - | - |
| Net revenues | 0 | 0 | - | - |
| Gross profit | 0 | 0 | - | - |
| Marketing expenses | 52 | 8 | 176 | 114 |
| General and administrative | 306,796 | 412,023 | 487,041 | 564,683 |
| Research and development | 29,681 | 7,482 | 8,842 | 206,161 |
| Stock based compensation | 50,000 | 50,000 | 50,000 | 37,500 |
| Total operating expenses | 386,529 | 469,513 | 546,059 | 808,458 |
| Loss from operations | -386,529 | -469,513 | -546,059 | -808,458 |
| Other income | 0 | 5,797 | - | - |
| Modification of warrants | 0 | 17,505 | - | 24,770 |
| Inducement of preferred shares | 0 | 845,901 | - | - |
| Interest expense | 2,024 | 873 | 448 | 850 |
| Interest expense - debt discount | 70,211 | 42,175 | 27,704 | 263,719 |
| Interest expense - original issuance costs | 119,739 | 81,017 | 94,353 | 99,126 |
| Total other expense | -191,974 | -981,674 | -122,505 | -388,465 |
| Loss before income taxes | -578,503 | -1,451,187 | -668,564 | -1,196,923 |
| Net loss | -578,503 | -1,451,187 | -668,564 | -1,196,923 |
| Net loss per share, basic | -0.36 | -0.9 | -0.42 | -0.94 |
| Net loss per share, diluted | -0.36 | -0.9 | -0.42 | -0.94 |
| Weighted average number of shares outstanding, basic | 1,605,377 | 1,605,377 | 1,605,377 | 1,268,795 |
| Weighted average number of shares outstanding, diluted | 1,605,377 | 1,605,377 | 1,605,377 | 1,268,795 |
Sigyn Therapeutics, Inc. (SIGY)
Sigyn Therapeutics, Inc. (SIGY)